CN201535769U - External transdermal diffusion device - Google Patents
External transdermal diffusion device Download PDFInfo
- Publication number
- CN201535769U CN201535769U CN2009203141025U CN200920314102U CN201535769U CN 201535769 U CN201535769 U CN 201535769U CN 2009203141025 U CN2009203141025 U CN 2009203141025U CN 200920314102 U CN200920314102 U CN 200920314102U CN 201535769 U CN201535769 U CN 201535769U
- Authority
- CN
- China
- Prior art keywords
- cylinder body
- diffusion device
- cover body
- transdermal diffusion
- groove
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The utility model relates to a medical experimental device, in particular to an external transdermal diffusion device. The utility model relates to an external transdermal diffusion device, and adopts the following technical scheme that the external transdermal diffusion device comprises a cylinder body 2, wherein two ends of the cylinder body 2 are open, one end of the cylinder body 2 is provided with a cover body 1 which is matched with the cylinder body, a groove is arranged on the upper surface of the cover body 1, the cross section of the cover body 1 is of concave shape, a clamping groove 4 is arranged on a side wall of the groove 3, and the cover body 1 and the cylinder body 2 are connected through screw threads or are clamped. The other end of the cylinder body 2 is used for fixing excised skin, the cover body 1 can be firmly clamped on a rotary rod of a dissolution determinator and used by matching with the dissolution determinator so as to uniformly control stirring rotation speed and bath temperature, and skin permeation tests in vitro in six parts are simultaneously operated in parallel, which maximally reduces the accident error, and saves time. The external transdermal diffusion device has the characteristics of low cost and capability of being modified by means of waste spool boxes, is beneficial for environment protection, and agrees with the theory of sustainable development.
Description
Technical field
The utility model relates to a kind of medical experimental provision, especially relates to a kind of transdermal test in vitro disperser.
Background technology
Transdermal delivery system (Transdermal Therapeutic System, TTS or Transdermal Drug DeliverySystem, TDDS), be meant in skin or mucous membrane surface administration, make medicine pass through each layer of skin or mucous membrane with constant speed (or near constant speed), enter the body circulation, produce the novel formulation of whole body or local therapeutic effects, it has the liver first-pass effect of avoiding and GI destruction, keep and stablize lasting blood concentration, that can be scheduled to and long action time are provided, avoided potential toxic and side effect of injecting drug use and oral medication and half life period short, shortcomings such as blood concentration instability improve bioavilability, reduce the medication number of times, providing convenience for chronic patient and infant, is the focus of third generation pharmaceutical preparation development research.
What nineteen sixty-five Stotlghton proposed medicine absorbs notion through skin, and first transdermal delivery system Zhao Scopolamine Patch obtained drugs approved by FDA in 1979, is used to prevent and treat that motion sickness causes feels sick, vomiting.Then FDA has ratified the anginal monobel skin-permeable and control-released plaster of control, other products go on the market in succession subsequently, comprise the hypertensive clonidine patch of treatment, the FemPatcs that is used for symptoms such as menopausal women hypogonadism, the nicotine patch of supplemental treatment is used to give up smoking, need to be used to the fentanyl patch of the chronic pain disorders of opium treatment, to be used for the treatment of the testosterone patch of testosterone deficiency disease, be used for the treatment of anginal ISDN etc.The domestic pasters such as hyoscine, monobel, clonidine, estradiol, nicotine and nitrendipine of also having succeeded in developing in succession.21 century China's development also is used for clinical levamisol smears, with the logotype of anti-hepatitis preparation, has obtained good effect.
The present TDDS product of U.S.'s approved more than 35, therapeutic domain relates to hypertension, angina pectoris, motion sickness, Woman climacteric, male gonad hypofunction, analgesia, smoking cessation supplemental treatment, contraception and treatment of urinary incontinence etc.TDDS just under development will further expand the treatment field, comprise the treatment low to Parkinson disease, attention deficit syndrome, hyperactivity and femal sexual function.At present, the interior speed increase of transdermal formulation new varieties quantity global range with every year 11.2%.According to statistics, preparation capable of permeating skin global marketing volume in 2000 has reached 6,700,000,000 dollars, and 2003 is 9,100,000,000 dollars, estimates can reach 80,000,000,000～1,000 hundred million dollars in 2010.
The transdermal test in vitro disperser is the essential equipment of research transdermal formulation, existing transdermal test in vitro disperser, the general stainless steel that adopts, its structure is two Room up and down, in the middle of skin histology is fixed in, its maximum inconvenience is: can not be used with dissolution test system, water bath with thermostatic control and rotational speed regulation need to be equipped with in addition, and cost an arm and a leg.For common laboratory, the experimental apparatus of buying multiple simple function has the certain economic burden, and causes waste.
Therefore study a kind of cheapness, convenience, to be beneficial to the transdermal test in vitro disperser of environmental protection accurately, again very necessary.
The utility model content
The purpose of this utility model is exactly to provide a kind of transdermal test in vitro disperser at the deficiency of above-mentioned existence.This transdermal test in vitro disperser is used for the skin permeation rate test experiments of drug transdermal absorbable preparation, can cooperate with dissolution test system easily, have conveniently, accurately, characteristics such as easy operating.
Transdermal test in vitro disperser technical scheme of the present utility model is, comprises cylindrical shell, it is characterized in that, described cylindrical shell both ends open, an end of this cylindrical shell are provided with the lid that cooperates with it; Described lid upper surface is a groove, and this lid cross section is " recessed " shape.
Characteristics of the present utility model also have: the sidewall of described groove is provided with draw-in groove; Described lid and cylindrical shell are by being threaded or clamping.
The beneficial effects of the utility model are: the mode that this device adopts cylindrical shell to combine with lid, and when experimentizing, isolated skin is fixed on the other end of cylindrical shell, and epidermis side is inside, and medicine is coated in epidermis side by the lid end, as diffuser casing; Lid is provided with groove, can be easily with this device card on the dwang of dissolution test system, be convenient to set rotating speed; Hold certain reception liquid in the stripping rotor of dissolution test system, as receiving chamber; The dwang of dissolution test system is descended, the interior surface of the isolated skin that is fixed on transdermal test in vitro disperser below is dipped in receives in the liquid, bath temperature is controlled at 37+0.5 ℃, starts motor, makes the dwang rotating speed be controlled at 50rpm.Thereby realized that this transdermal test in vitro disperser cooperates laboratory dissolution test system commonly used to use, solved the problem of the unified control of rotating speed and bath temperature simultaneously, and 6 parts of parallel laboratory tests simultaneously, reduced error to greatest extent, saved the time.This device adopts the manufacturing of medical engineering plastics in addition, further avoided the laboratory to buy expensive instrument and the waste that causes, and this device is not fragile, can use repeatedly.
Description of drawings:
Figure 1 shows that structural representation of the present utility model;
Figure 2 shows that cut-open view of the present utility model;
Figure 3 shows that the utility model is installed in the synoptic diagram of dissolution test system dwang lower end.
Wherein, 1. lid, 2. cylindrical shell, 3. groove, 4. draw-in groove, 5. dissolution test system dwang, 6. isolated skin, 7. rubber band, 8. dissolution test system stripping rotor, 9. transdermal receives liquid.
Embodiment:
In order to understand the utility model better, describe the technical solution of the utility model in detail below in conjunction with accompanying drawing.
By Fig. 1, Fig. 2 as can be seen, this transdermal test in vitro disperser comprises cylindrical shell 2, and described cylindrical shell 2 both ends opens, an end of this cylindrical shell 2 are provided with the lid 1 that cooperates with it; Described lid 1 upper surface is a groove 3, and this lid 1 cross section is " recessed " shape, and is simple in structure, easy to use.Described cylindrical shell 2 is worked in coordination with lid 1, can cooperate with cylindrical shell 2 cylindricals for lid 1, also can be provided with according to actual needs to get final product for lid 1 cooperates with circle in the cylindrical shell 2.
As can be seen from Figure 2, the sidewall of described groove 3 is provided with draw-in groove 4, can carry out clamping with the dwang 5 of dissolution test system, thereby further improve fastness.
Described lid 1 and cylindrical shell 2 are by being threaded or clamping.
This device material is the medical engineering plastics.
Operation when experimentizing is described: isolated skin 6 epidermis side are inwardly wrapped up the end that cylindrical shell 2 is not connected with lid 1, and it is fixing with rubber band 7, lid 1 is opened, smear transdermal absorption formulation by lid 1 end in isolated skin 6 epidermis side, calculate its effective diffusion area according to the diameter of cylindrical shell 2.Lid 1 is covered, and be fixed on dwang 5 lower ends of dissolution test system, cylindrical shell 2 lower end rubber bands 7 are inserted transdermal with the lower part receive in the liquid 9, can regulate suitable rotating speed transdermal reception liquid 9 is stirred; Utilize the stripping rotor of dissolution test system to be the transdermal drug receiving chamber, be convenient to control suitable bath temperature, realized the purpose of 6 parts of experiment operation repetitives, reduced experimental error to greatest extent, saved the time.
The technical solution of the utility model can realize that make things convenient for, be easy to get, concrete steps are as follows by the transformation to discarded spool box:
The spool box bottom is sliced off and polishes with sand paper; With the epidermis side of isolated skin inwards, wrap and fix from the spool box bottom with rubber band; The film lid is opened, smeared transdermal absorption formulation in the epidermis side of isolated skin, calculating its effective diffusion area according to the diameter (uniform specification) of spool box is 4.1cm
2Cover the film lid, the film lid is stuck on three metal-toothed of dwang lower end of dissolution test system (size is just suitable), can regulate suitable rotating speed and transdermal is received liquid stir; Dwang is descended, the lower end rubber band of spool box is inserted in the transdermal reception liquid with the lower part, utilize the stripping rotor of dissolution test system to be the transdermal drug receiving chamber, be convenient to regulate suitable bath temperature, test.Characteristics are: cheap, be easy to get, diffusion area is accurate, coating is convenient, can use repeatedly, and has realized 6 parts of purposes that experiment is carried out simultaneously, has saved the time, owing to operation repetitive, so reduced error to greatest extent.Be the utilization again of old and useless article, help environmental protection, meet sustained development theory.
Application mode described in the utility model can be adjusted according to actual conditions, is not to be used for limiting the utility model.
Claims (3)
1. a transdermal test in vitro disperser comprises cylindrical shell, it is characterized in that, described cylindrical shell both ends open, an end of this cylindrical shell are provided with the lid that cooperates with it; Described lid upper surface is a groove, and this lid cross section is " recessed " shape.
2. transdermal test in vitro disperser according to claim 1 is characterized in that the sidewall of described groove is provided with draw-in groove.
3. according to the described transdermal test in vitro disperser of claim 1, it is characterized in that described lid and cylindrical shell are by being threaded or clamping.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009203141025U CN201535769U (en) | 2009-11-05 | 2009-11-05 | External transdermal diffusion device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009203141025U CN201535769U (en) | 2009-11-05 | 2009-11-05 | External transdermal diffusion device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201535769U true CN201535769U (en) | 2010-07-28 |
Family
ID=42535548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009203141025U Expired - Fee Related CN201535769U (en) | 2009-11-05 | 2009-11-05 | External transdermal diffusion device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201535769U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103299961A (en) * | 2013-05-31 | 2013-09-18 | 江苏省血吸虫病防治研究所 | Device and method for in-vitro preparation of schistosomulum |
| US11709160B2 (en) | 2016-05-20 | 2023-07-25 | The University Of Dundee | Skin sample culture apparatus |
-
2009
- 2009-11-05 CN CN2009203141025U patent/CN201535769U/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103299961A (en) * | 2013-05-31 | 2013-09-18 | 江苏省血吸虫病防治研究所 | Device and method for in-vitro preparation of schistosomulum |
| CN103299961B (en) * | 2013-05-31 | 2015-08-12 | 江苏省血吸虫病防治研究所 | A kind of external device and method preparing schistosomulum |
| US11709160B2 (en) | 2016-05-20 | 2023-07-25 | The University Of Dundee | Skin sample culture apparatus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW565462B (en) | A novel composition for transdermal administration of estrogen, progestin or a mixture thereof | |
| ES2300820T3 (en) | PHARMACEUTICAL COMPOSITION TRANSDERMICA. | |
| TW200815045A (en) | Pharmaceutical compositions of ropinirole and methods of use thereof | |
| CN101621999A (en) | The transdermal formulation that percutaneous absorbs medical composition, medical composition storage element and utilized this storage element | |
| Bala et al. | Transdermal drug delivery system (TDDS)-a multifaceted approach for drug delivery | |
| CN101304734A (en) | Transdermal drug delivery devices containing O-desmethyl venlafaxine (ODV) or its salts | |
| CN201535769U (en) | External transdermal diffusion device | |
| KR20170131542A (en) | Oral application meterial containing polymeric medical ingredient, and method for administering polymeric medical ingredient to oral cavity | |
| JP5350575B2 (en) | Sheet-like pack and method for producing the same | |
| CN209316551U (en) | A kind of solubility microneedle patch | |
| CN107029343B (en) | A kind of portable cutaneous penetration patch instrument and preparation method thereof | |
| CN107441063A (en) | A kind of mixed gel skeleton brufen cataplasm and its preparation technology | |
| JP2011088862A (en) | Diclofenac sodium-containing aqueous plaster | |
| CN104013603A (en) | Nicotine slow-release patch | |
| CN109481422B (en) | Graphene oxide electrothermal film transdermal patch | |
| CN110573160B (en) | Adhesive patch | |
| CN1056772C (en) | Carsickness plaster and carsickness drug | |
| CN108289859A (en) | System and method for cutaneous penetration | |
| TW201223528A (en) | Transdermal absorption preparation | |
| CN109481423A (en) | A kind of diclofenac salt transdermal patch and preparation method thereof | |
| CN108211108A (en) | A kind of microvesicle patch and preparation method being administered continuously for acupuncture point | |
| TWI815062B (en) | Methods for improving the retention of the adhesive layer of patches containing ropinirole, and improving the retention of patches containing ropinirole | |
| CN105534880A (en) | PVA/TA-beta-CD composite hdyrogel, and matrix and preparation method thereof | |
| Shinde et al. | REVIEW OF TRANSDERMAL DRUG DELIVERY SYSTEM | |
| JPH0436133B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100728 Termination date: 20111105 |